

# CANCER GENOMICS & PROTEOMICS

**Published by the International Institute of Anticancer Research**

ISSN (print): 1109-6535; ISSN (online): 1790-6245

**Volume 7, 2010**

**INDEX**



## Editorial Board

- A. Seth** Editor-in-Chief  
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,  
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland  
**R. Abagyan** The Scripps Research Institute, La Jolla, CA, USA  
**F. Ahmed** Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA  
**S. Antonarakis** Division of Medical Genetics, University of Geneva Medical School, Switzerland  
**D.-T. Bau** Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan  
**A.M. Burger** Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA  
**M.R. Chance** Case Western Reserve University, Center for Proteomics and Bioinformatics, Cleveland, OH, USA  
**A.M. Chinnaiyan** Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA  
**B.F.C. Clark** Department of Molecular Biology, University of Aarhus, Denmark  
**R. Clarke** Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA  
**N. E. Davidson** University of Pittsburgh, Cancer Institute, Pittsburgh, PA, USA  
**I. Dunham** European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UK  
**T. Efferth** Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany  
**J.A. Fernandes-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA  
**C.V. Forst** Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA  
**M. Fountoulakis** F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland  
**D.S. Gerhard** NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA  
**J.W. Gray** Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA  
**B.B. Haab** Van Andel Research Institute, Grand Rapids, MI, USA  
**C.-H. Heldin** Ludwig Institute for Cancer Research, Uppsala, Sweden  
**J.D. Hoheisel** Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany  
**R.P. Huang** RayBiotech, Inc., Norcross, GA, USA  
**T.H.M. Huang** Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA  
**S.C. Jhanwar** Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA  
**V.C. Jordan** Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA  
**J. Ju** Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA  
**A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland  
**O.P. Kallioniemi** Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland  
**K. Khalili** College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- D.G. Kieback** Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Dresden, Germany  
**S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece  
**B. Léyland-Jones** Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA  
**P. Lichter** Deutsches Krebsforschungszentrum, Heidelberg, Germany  
**A. Lindblom** Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden  
**G. Lubec** Department of Pediatrics, University of Vienna, Austria  
**J. Lyons-Weiler** Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA  
**P.J. McCormick** The Center for Functional Genomics, Gen\*NY\*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA  
**F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden  
**P. Nelson** Fred Hutchinson Cancer Research Center, Seattle, WA, USA  
**C. Nicot** Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
- L. O'Driscoll** School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland  
**I. Pastan** Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA

<b>C.D. Platsoucas</b>	College of Sciences, Old Dominion University, Norfolk, VA, USA
<b>J. Quackenbush</b>	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
<b>J.S. Rader</b>	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
<b>A. Raouf</b>	Department of Immunology, University of Manitoba, Manitoba Institute of Cell Biology (MICB), Winnipeg, MB, Canada
<b>G. Rasty</b>	Department of Anatomic Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
<b>G. Rechavi</b>	Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
<b>R.H. Reeves</b>	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
<b>K.L. Reichelt</b>	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
<b>T. Ried</b>	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
<b>G. Rimbach</b>	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
<b>K.D. Rodland</b>	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
<b>Y. Sakaki</b>	Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan
<b>C. Sansom</b>	The School of Crystallography, Birbeck College, University of London, UK
<b>N.A. Saunders</b>	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
<b>J. Schneider</b>	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
<b>O.J. Semmes</b>	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
<b>G.V. Sherbet</b>	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
<b>K.K. Singh</b>	Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA
<b>S. Smith</b>	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
<b>J.C. Strefford</b>	Cancer Science Division, Southampton General Hospital, Southampton, UK
<b>J.M. Trent</b>	Tgen, Phoenix, AZ, USA
<b>G. Tsangaris</b>	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
<b>L.-C. Tsui</b>	The Hospital for Sick Children, University of Toronto, ON, Canada
<b>G.F. Vande Woude</b>	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
<b>D.K. Watson</b>	Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
<b>K. Williams</b>	Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA
<b>A.T. Yeung</b>	Fox Chase Cancer Center, Philadelphia, PA, USA
<b>H. Zhang</b>	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

#### **Editorial Office:**

International Institute of Anticancer Research  
 1st km Kapandritiou-Kalamou Road,  
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.  
 Tel: +30 22950 52945, Fax: +30 22950 53389  
 e-mail: journals@iiar-anticancer.org. Web: www.iiar-anticancer.org; www.iiarjournals.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

## Acknowledgements

The following Organisations supported many of the works published in *CANCER GENOMICS & PROTEOMICS*, Volume 7, 2010.

AIF-ProInno, Germany	Ministry of Higher Education, Kingdom of Saudi Arabia
Albert Hung Foundation, UK	
Association Grenobloise d'Etude de la Cellule Cancéreuse (AGECC), France	National Cancer Institute (NCI), NIH, Bethesda, MD, U.S.A.
	National Health and Medical Research Council, Canberra, Australia
Cancer Research Wales, Cardiff, UK	National Natural Science Foundation, People's Republic of China
	National University of Ireland (NUI), Dublin, Ireland
Deutsche Forschungsgemeinschaft (DFG; German Research Association), Bonn, Germany	New Star Plan of Science and Technology, Beijing, China
Deutsche Krebshilfe, Bonn, Germany	
	Science Foundation Ireland (SFI), Dublin, Ireland
East Carolina University, Greenville, NC, U.S.A.	Sigma Xi, The Scientific Research Society, Research Triangle Park, NC, U.S.A.
	Stiftelsen Gävle Cancerfond, Sweden
Harvard Catalyst, The Harvard Clinical and Translational Science Center, Boston, MA, U.S.A.	Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond, Uppsala, Sweden
Irish Research Council for Science, Engineering & Technology, Dublin, Ireland	
	Wessex Medical Research, Southampton, UK
Ministry of Education, Culture, Sports, Science and Technology, Japan	

## Contents, Volume 7, 2010

### Number 1

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM ( <i>Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India</i> ) .....	1
DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL ( <i>Pomona, CA, USA</i> ) .....	9
Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA ( <i>Shizuoka; Tokyo; Saitama, Japan</i> ) .....	17
Mast Cells in Squamous Cell Esophageal Carcinoma and Clinical Parameters. B. TINGE, D. MOLIN, M. BERGQVIST, S. EKMAN, S. BERGSTRÖM ( <i>Uppsala, Sweden</i> ) .....	25
* Review: Genetic Basis and Gene Therapy Trials for Thyroid Cancer. H. AL-HUMADI, A. ZARROS, R. AL-SAIGH, C. LIAPI ( <i>Athens, Greece</i> ) .....	31
* Review (page 31)	

### Number 2

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene <i>TFPI2</i> in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ ( <i>Düsseldorf, Germany</i> ) .....	51
Spontaneous <i>In Vitro</i> Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA ( <i>Muenchen; Düsseldorf; Rostock, Germany</i> ) .....	61
Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG ( <i>Cardiff, UK; Beijing, PRC</i> ) .....	67
The Transcript Expression and Protein Distribution Pattern in Human Colorectal Carcinoma Reveal a Pivotal Role of <i>COM-1/p8</i> as a Tumour Suppressor. M.L. DAVIES, C. PARR, A.J. SANDERS, O. FODSTAD, W.G. JIANG ( <i>Wales, UK; Alabama, USA</i> ) .....	75
Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS ( <i>Berlin, Germany</i> ) .....	81
Inhibition of c-Jun N-terminal Kinase by SP600125: A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.-P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN ( <i>Grenoble, France</i> ) .....	87

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. AL-RUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND ( <i>Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA</i> ) .....	93
* Mini Review: The Role of Folate Metabolism-related Gene Polymorphisms in the Development of Meningiomas. S.S. DRAKOS, F. ANIFANTAKI, A. ZARROS, C. LIAPI ( <i>Athens, Greece</i> ) .....	105
* Mini Review (page 105)	

### Number 3

Use of Cross Species Genomic Profiling Identifies Pathways and Genes Differentially Regulated in Prostate Cancer Cells Treated with Soy Protein Isolates or Purified Genistein. M.A. LISS, M. SCHLICHT, A. DEGUEME, M. HESSNER, M.W. DATTA ( <i>Irvine, CA; Chicago, IL; Milwaukee, WI; Minneapolis, MN, USA</i> ) .....	111
A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG. R.-P. HUANG ( <i>Guangzhou, P.R. China</i> ) .....	129
Genomic Analysis of the 55 kDa Subunit of DNA Polymerase $\epsilon$ in Human Intracranial Neoplasms. Q. ZHOU, T. LEHTONEN, J. LEHTONEN, S. LAAKSO, J. SZYMAS, H. POSPIECH, K. HUOPONEN, J. SYVÄOJA, Y. COLLAN ( <i>Turku; Oulu; Joensuu, Finland; Poznan, Poland</i> ) .....	143
Identification of Serpin ( $\alpha$ -1-Antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.H. ZIGANSHIN, N. YU. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH ( <i>Moscow, Russia; Mainz, Germany</i> ) .....	147
* Review: Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER ( <i>Penzberg, Germany; Vienna, Austria</i> ) .....	157
Errata .....	171
* Review (page 171)	

### Number 4

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER ( <i>Regensburg; Munich, Germany</i> ) .....	173
Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU ( <i>Kanagawa, Japan</i> ) .....	181
Inhibition of P-glycoprotein at the Blood-Brain Barrier by Phytochemicals Derived from Traditional Chinese Medicine. A. MAHRINGER, S. KARAMUSTAFA, D. KLOTZ, S. KAHL, V.B. KONKIMALLA, Y. WANG, J. WANG, H.-Y. LIU, H. BOECHZELT, X. HAO, R. BAUER, G. FRICKER, T. EFFERTH ( <i>Heidelberg, Germany; Graz, Austria; Kunming, P.R. China</i> ) .....	191
Evolutionary Expansion of Structurally Complex DNA Sequences. S.S. SMITH ( <i>Duarte, CA, USA</i> ) .....	207

\* Review: *TGF-β1* Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*) ..... 217

\* Review (page 217)

**Number 5**

\* Review: ALCAM/CD166: Cancer-related Issues. U.H. WEIDLE, D. EGGLE, S. KLOSTERMANN, G.W.M. SWART (*Penzberg, Germany; Nijmegen, Netherlands*) ..... 231

Characterization of Soy-based Changes in Wnt-Frizzled Signaling in Prostate Cancer. M.A. LISS, M. SCHLICHT, A. KAHLER, R. FITZGERALD, T. THOMASSI, A. DEGUEME, M. HESSNER, M.W. DATTA (*Irvine, CA; Chicago, IL; Milwaukee, WI; Boston, MA; Atlanta, GA; Minneapolis, MN, USA*) ..... 245

Tyrosine Kinase-Deficient EphB6 Receptor-dependent Alterations in Proteomic Profiles of Invasive Breast Carcinoma Cells as Determined by Difference Gel Electrophoresis. R.P. KANDPAL (*Pomona, CA, USA*)..... 253

MicroRNA Expression Profile of MCF-7 Human Breast Cancer Cells and the Effect of Green Tea Polyphenon-60. L.N. FIX, M. SHAH, T. EFFERTH, M.A. FARWELL, B. ZHANG (*Greenville, NC, USA; Mainz, Germany*) ..... 261

Analysis of Protein Phosphorylation in Cisplatin-Treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*) ..... 279

\* Review (page 231)

**Number 6**

\* Review: Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Penzberg; Munich, Germany*) ..... 287

Surface Plasmon Resonance (SPR) Spectrometry as a Tool to Analyze Nucleic Acid-Protein Interactions in Crude Cellular Extracts. F.E. AHMED, J.E. WILEY, D.A. WEIDNER, C. BONNERUP, H. MOTA (*Greenville, NC, USA*) ..... 303

Circadian Transcription Profile of Mouse Breast Cancer Under Light-Dark and Dark-Dark Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*) ..... 311

Effects of DNA Minor Groove Binding Agents on Global Gene Expression. M. ZIHLIF, D.R. CATCHPOOLE, B.W. STEWART, L.P.G. WAKELIN (*Amman, Jordan; Westmead; Randwick; Sydney, NSW, Australia*) ..... 323

Apoptotic Regulators: P53 and Survivin Expression in Non-small Cell Lung Cancer. I. PORĘBSKA, E. SOBAŃSKA, M. KOSACKA, R. JANKOWSKA (*Wroclaw, Poland*)..... 331

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)..... 337

Errata ..... 347

Index 2010 ..... 349

\* Review (page 287)



## Subject Index

(Figures refer to page numbers)

- 11q23 Aberration, NG2, acute myeloid leukemia, 173  
 Acute myeloid leukemia, NG2, 11q23 aberration, 173  
 Adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, prognostic marker, target validation, therapeutic intervention, ALCAM/CD166, review, 231  
 Affinity enrichment, binding, biosensor, kinetics, label-free, mass, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303  
 ALCAM/CD166, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, prognostic marker, target validation, therapeutic intervention, review, 231  
 Angiogenesis, CD147 antibodies, matrix metallo-proteinase(s), protein-protein interactions, target validation experiments, review, 157  
 Annexin V, apoptotic cell isolation, RPA, Erk1/2, cisplatin, multi-antibody screening, protein phosphorylation, 279  
 Antibody arrays, cytokines, ovarian cancer, gynecological malignancy, diagnosis, protein expression, 129  
 Anticancer activity, artemisinin, cell cycle arrest, cytokinesis, mitotic checkpoint genes, 337  
 Antisense approach, thyroid cancer, genetic basis, gene therapy trials, mutations, combination approach, toxic gene therapy approach, review, 31  
 A-1-Antitrypsin, biological therapy, cancer therapy, proteomics, serpin, Ehrlich carcinoma, 147  
 Apoptosis, cell cycle regulation, endoreplication, microarray, c-jun *N*-terminal kinase, SP600125, 87  
 Apoptosis, immunohistochemistry, tumour marker, p53, survivin, non-small cell lung cancer, 331  
 Apoptotic cell isolation, RPA, Erk1/2, cisplatin, multi-antibody screening, annexin V, protein phosphorylation, 279  
 Artemisinin, anticancer activity, cell cycle arrest, cytokinesis, mitotic checkpoint genes, 337  
 Astrocytoma, brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), genomic changes, metastasis, glioblastoma, atypical meningioma, 143  
 Atypical meningioma, brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), genomic changes, metastasis, glioblastoma, astrocytoma, 143  
 Autoantibody, malignant melanoma, melanoma markers, two-dimensional gel electrophoresis, 2-DE, serological proteome approach, SERPA, 17  
 Beta catenin, prostate cancer, soy protein, genistein, frizzled, gene expression, Wnt-frizzled signaling, 245  
 Beta catenin, prostate cancer, soy protein, genistein, metabolic pathway, gene expression, 111  
 Binding, affinity enrichment, biosensor, kinetics, label-free, mass, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303  
 Biological therapy, cancer therapy, proteomics, serpin, a-1-antitrypsin, Ehrlich carcinoma, 147  
 Biomarkers, mass spectrometry, prostate cancer, progression, serum proteomic analysis, SELDI-TOF-MS, 93  
 Biosafety, immortalization, primary human osteoblast-like cells, chromosome rearrangement, 61  
 Biosensor, affinity enrichment, binding, kinetics, label-free, mass, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303  
 Bisulphite sequencing, *TFPI2*, imprinting, prostate cancer, chromatin immunoprecipitation, DNA methylation, 51  
 Bladder cancer, S100A8, S100A9, serum, proteomics, immunohistochemistry, clinical outcome, 181  
 Brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), genomic changes, metastasis, glioblastoma, astrocytoma, atypical meningioma, 143  
 Breast cancer invasiveness, DNA-based assay, MSP, circulating tumor cells, EPHB6, metastasis, 9  
 Breast cancer invasiveness, mass spectrometry, difference gel electrophoresis, DIGE, proteomic profile, EPHB6, metastasis, tyrosine kinase-deficient, 253  
 Breast cancer, circadian, microarray, gene expression, 311  
 Breast cancer, green tea, micro-RNA, microarray, gene expression, Polyphenon-60, MCF-7, 261  
 Breast cancer, TACC2, transcript analysis, survival, prognosis, 67  
 Bufadienolides, calcein assay, P-glycoprotein, multidrug resistance, natural products, phytochemicals, pharmacogenomics, 191  
 Cachexia, interleukin 6, interleukin 6 receptor, cancer, review, 287  
 Calcein assay, bufadienolides, P-glycoprotein, multidrug resistance, natural products, phytochemicals, pharmacogenomics, 191  
 Cancer therapy, biological therapy, proteomics, serpin, a-1-antitrypsin, Ehrlich carcinoma, 147  
 Cancer, interleukin 6, interleukin 6 receptor, cachexia, review, 287  
 CD147 antibodies, angiogenesis, matrix metallo-proteinase(s), protein-protein interactions, target validation experiments, review, 157  
 Cell cycle arrest, anticancer activity, artemisinin, cytokinesis, mitotic checkpoint genes, 337  
 Cell cycle regulation, apoptosis, endoreplication, microarray, c-jun *N*-terminal kinase, SP600125, 87  
 Chromatin immunoprecipitation, *TFPI2*, imprinting, prostate cancer, bisulphite sequencing, DNA methylation, 51  
 Chromosome rearrangement, immortalization, primary human osteoblast-like cells, biosafety, 61  
 Circadian, microarray, breast cancer, gene expression, 311  
 Circulating tumor cells, DNA-based assay, MSP, EPHB6, breast cancer invasiveness, metastasis, 9  
 Cisplatin, apoptotic cell isolation, RPA, Erk1/2, multi-antibody screening, annexin V, protein phosphorylation, 279  
 C-jun *N*-terminal kinase, cell cycle regulation, apoptosis, endoreplication, microarray, SP600125, 87

- Clinical outcome, S100A8, S100A9, bladder cancer, serum, proteomics, immunohistochemistry, 181
- Colorectal carcinoma, *COM-1*, *p8*, metastasis, 75
- COM-1*, *p8*, colorectal carcinoma, metastasis, 75
- Combination approach, thyroid cancer, genetic basis, gene therapy trials, mutations, antisense approach, toxic gene therapy approach, review, 31
- Cyclin D1, laryngeal carcinoma, Ki-67, MSH2, p53, tissue microarray, immunohistochemistry, profiling, radiotherapy, 1
- Cystathione- $\beta$ -synthase, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, review, 105
- Cytokines, antibody arrays, ovarian cancer, gynecological malignancy, diagnosis, protein expression, 129
- Cytokinesis, anticancer activity, artemisinin, cell cycle arrest, mitotic checkpoint genes, 337
- 2-DE, Malignant melanoma, autoantibody, melanoma markers, two-dimensional gel electrophoresis, serological proteome approach, SERPA, 17
- Diagnosis, antibody arrays, cytokines, ovarian cancer, gynecological malignancy, protein expression, 129
- Diagnostics, transforming growth factor- $\beta$ 1, interactome, metastasis, therapeutics, review, 217
- Difference gel electrophoresis, mass spectrometry, DIGE, proteomic profile, EPHB6, breast cancer invasiveness, metastasis, tyrosine kinase-deficient, 253
- DIGE, mass spectrometry, difference gel electrophoresis, proteomic profile, EPHB6, breast cancer invasiveness, metastasis, tyrosine kinase-deficient, 253
- Dissemination and metastasis, adhesion and aggregation, homo- and heterophilic interactions, malignant melanoma, prognostic marker, target validation, therapeutic intervention, ALCAM/CD166, review, 231
- DNA binding, gene expression, minor groove binders, 323
- DNA methylation, *TFPI2*, imprinting, prostate cancer, bisulphite sequencing, chromatin immunoprecipitation, 51
- DNA polymerase epsilon ( $\epsilon$ ), brain neoplasms, genomic changes, metastasis, glioblastoma, astrocytoma, atypical meningioma, 143
- DNA-based assay, MSP, circulating tumor cells, EPHB6, breast cancer invasiveness, metastasis, 9
- Ehrlich carcinoma, biological therapy, cancer therapy, proteomics, serpin, a-1-antitrypsin, 147
- Endoreplication, cell cycle regulation, apoptosis, microarray, c-jun *N*-terminal kinase, SP600125, 87
- EPHB6, DNA-based assay, MSP, circulating tumor cells, breast cancer invasiveness, metastasis, 9
- EPHB6, mass spectrometry, difference gel electrophoresis, DIGE, proteomic profile, breast cancer invasiveness, metastasis, tyrosine kinase-deficient, 253
- Epigenetics, triplex, i-motif, Quadruplex, non-B DNA structure, evolution, scaling developmental complexity, 207
- Erk1/2, apoptotic cell isolation, RPA, cisplatin, multi-antibody screening, annexin V, protein phosphorylation, 279
- Errata, 171, 347
- Esophageal carcinoma, mast cells, survival, 25
- Evolution, triplex, i-motif, Quadruplex, non-B DNA structure, epigenetics, scaling developmental complexity, 207
- Folate metabolism, meningiomas, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Frizzled, prostate cancer, soy protein, genistein, beta catenin, gene expression, Wnt-frizzled signaling, 245
- Gene expression, circadian, microarray, breast cancer, 311
- Gene expression, DNA binding, minor groove binders, 323
- Gene expression, green tea, micro-RNA, microarray, Polyphenon-60, breast cancer, MCF-7, 261
- Gene expression, prostate cancer, soy protein, genistein, beta catenin, frizzled, Wnt-frizzled signaling, 245
- Gene expression, prostate cancer, soy protein, genistein, beta catenin, metabolic pathway, 111
- Gene polymorphisms, meningiomas, folate metabolism, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Gene therapy trials, thyroid cancer, genetic basis, mutations, antisense approach, combination approach, toxic gene therapy approach, review, 31
- Genetic basis, thyroid cancer, gene therapy trials, mutations, antisense approach, combination approach, toxic gene therapy approach, review, 31
- Genistein, prostate cancer, soy protein, beta catenin, frizzled, gene expression, Wnt-frizzled signaling, 245
- Genistein, prostate cancer, soy protein, beta catenin, metabolic pathway, gene expression, 111
- Genomic changes, brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), metastasis, glioblastoma, astrocytoma, atypical meningioma, 143
- Glioblastoma, brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), genomic changes, metastasis, astrocytoma, atypical meningioma, 143
- Green tea, micro-RNA, microarray, gene expression, Polyphenon-60, breast cancer, MCF-7, 261
- Gynecological malignancy, antibody arrays, cytokines, ovarian cancer, diagnosis, protein expression, 129
- Homo- and heterophilic interactions, adhesion and aggregation, dissemination and metastasis, malignant melanoma, prognostic marker, target validation, therapeutic intervention, ALCAM/CD166, review, 231
- Immortalization, primary human osteoblast-like cells, chromosome rearrangement, biosafety, 61
- Immunohistochemistry, apoptosis, tumour marker, p53, survivin, non-small cell lung cancer, 331
- Immunohistochemistry, laryngeal carcinoma, Ki-67, MSH2, p53, cyclin D1, tissue microarray, profiling, radiotherapy, 1
- Immunohistochemistry, S100A8, S100A9, bladder cancer, serum, proteomics, clinical outcome, 181
- I-motif, triplex, Quadruplex, non-B DNA structure, epigenetics, evolution, scaling developmental complexity, 207
- Imprinting, *TFPI2*, prostate cancer, bisulphite sequencing, chromatin immunoprecipitation, DNA methylation, 51
- Interactome, transforming growth factor- $\beta$ 1, diagnostics, metastasis, therapeutics, review, 217

- Interleukin 6 receptor, interleukin 6, cachexia, cancer, review, 287
- Interleukin 6, interleukin 6 receptor, cachexia, cancer, review, 287
- Ki-67, laryngeal carcinoma, MSH2, p53, cyclin D1, tissue microarray, immunohistochemistry, profiling, radiotherapy, 1
- Kinetics, affinity enrichment, binding, biosensor, label-free, mass, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303
- Label-free, affinity enrichment, binding, biosensor, kinetics, mass, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303
- Laryngeal carcinoma, Ki-67, MSH2, p53, cyclin D1, tissue microarray, immunohistochemistry, profiling, radiotherapy, 1
- Malignant melanoma, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, prognostic marker, target validation, therapeutic intervention, ALCAM/CD166, review, 231
- Malignant melanoma, autoantibody, melanoma markers, two-dimensional gel electrophoresis, 2-DE, serological proteome approach, SERPA, 17
- Mass spectrometry, biomarkers, prostate cancer, progression, serum proteomic analysis, SELDI-TOF-MS, 93
- Mass spectrometry, difference gel electrophoresis, DIGE, proteomic profile, EPHB6, breast cancer invasiveness, metastasis, tyrosine kinase-deficient, 253
- Mass, affinity enrichment, binding, biosensor, kinetics, label-free, probe, photons, nucleic acid-protein interactions, SPR spectroscopy, 303
- Mast cells, esophageal carcinoma, survival, 25
- Matrix metallo-proteinase(s), angiogenesis, CD147 antibodies, protein-protein interactions, target validation experiments, review, 157
- MCF-7, green tea, micro-RNA, microarray, gene expression, Polyphenon-60, breast cancer, 261
- Melanoma markers, malignant melanoma, autoantibody, two-dimensional gel electrophoresis, 2-DE, serological proteome approach, SERPA, 17
- Meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Metabolic pathway, prostate cancer, soy protein, genistein, beta catenin, gene expression, 111
- Metalloproteins, selenium, prostate, prostate carcinoma, 81
- Metastasis, brain neoplasms, DNA polymerase epsilon ( $\epsilon$ ), genomic changes, glioblastoma, astrocytoma, atypical meningioma, 143
- Metastasis, *COM-1*, p8, colorectal carcinoma, 75
- Metastasis, DNA-based assay, MSP, circulating tumor cells, EPHB6, breast cancer invasiveness, 9
- Metastasis, mass spectrometry, difference gel electrophoresis, DIGE, proteomic profile, EPHB6, breast cancer invasiveness, tyrosine kinase-deficient, 253
- Metastasis, transforming growth factor- $\beta$ 1, diagnostics, interactome, therapeutics, review, 217
- Methionine synthase reductase, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Methionine synthase, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Methylenetetrahydrofolate reductase, meningiomas, folate metabolism, gene polymorphisms, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Microarray, cell cycle regulation, apoptosis, endoreplication, c-jun *N*-terminal kinase, SP600125, 87
- Microarray, circadian, breast cancer, gene expression, 311
- Microarray, green tea, micro-RNA, gene expression, Polyphenon-60, breast cancer, MCF-7, 261
- Micro-RNA, green tea, microarray, gene expression, Polyphenon-60, breast cancer, MCF-7, 261
- Minor groove binders, gene expression, DNA binding, 323
- Mitotic checkpoint genes, anticancer activity, artemisinin, cell cycle arrest, cytokinesis, 337
- MSH2, laryngeal carcinoma, Ki-67, p53, cyclin D1, tissue microarray, immunohistochemistry, profiling, radiotherapy, 1
- MSP, DNA-based assay, circulating tumor cells, EPHB6, breast cancer invasiveness, metastasis, 9
- Multi-antibody screening, apoptotic cell isolation, RPA, Erk1/2, cisplatin, annexin V, protein phosphorylation, 279
- Multidrug resistance, bufadienolides, calcein assay, P-glycoprotein, natural products, phytochemicals, pharmacogenomics, 191
- Mutations, thyroid cancer, genetic basis, gene therapy trials, antisense approach, combination approach, toxic gene therapy approach, review, 31
- Natural products, bufadienolides, calcein assay, P-glycoprotein, multidrug resistance, phytochemicals, pharmacogenomics, 191
- NG2, acute myeloid leukemia, 11q23 aberration, 173
- Non-B DNA structure, triplex, i-motif, Quadruplex, epigenetics, evolution, scaling developmental complexity, 207
- Non-small cell lung cancer, apoptosis, immunohistochemistry, tumour marker, p53, survivin, 331
- Nucleic acid-protein interactions, affinity enrichment, binding, biosensor, kinetics, label-free, mass, probe, photons, SPR spectroscopy, 303
- Ovarian cancer, antibody arrays, cytokines, gynecological malignancy, diagnosis, protein expression, 129
- P53, apoptosis, immunohistochemistry, tumour marker, survivin, non-small cell lung cancer, 331
- P53, laryngeal carcinoma, Ki-67, MSH2, cyclin D1, tissue microarray, immunohistochemistry, profiling, radiotherapy, 1
- P8, *COM-1*, colorectal carcinoma, metastasis, 75
- P-glycoprotein, bufadienolides, calcein assay, multidrug resistance, natural products, phytochemicals, pharmacogenomics, 191
- Pharmacogenomics, bufadienolides, calcein assay, P-glycoprotein, multidrug resistance, natural products, phytochemicals, 191

- Photons, affinity enrichment, binding, biosensor, kinetics, label-free, mass, probe, nucleic acid-protein interactions, SPR spectroscopy, 303
- Phytochemicals, bufadienolides, calcein assay, P-glycoprotein, multidrug resistance, natural products, pharmacogenomics, 191
- Polyphenon-60, green tea, micro-RNA, microarray, gene expression, breast cancer, MCF-7, 261
- Primary human osteoblast-like cells, immortalization, chromosome rearrangement, biosafety, 61
- Probe, affinity enrichment, binding, biosensor, kinetics, label-free, mass, photons, nucleic acid-protein interactions, SPR spectroscopy, 303
- Profiling, laryngeal carcinoma, Ki-67, MSH2, p53, cyclin D1, tissue microarray, immunohistochemistry, radiotherapy, 1
- Prognosis, TACC2, breast cancer, transcript analysis, survival, 67
- Prognostic marker, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, target validation, therapeutic intervention, ALCAM/CD166, review, 231
- Progression, biomarkers, mass spectrometry, prostate cancer, serum proteomic analysis, SELDI-TOF-MS, 93
- Prostate cancer, biomarkers, mass spectrometry, progression, serum proteomic analysis, SELDI-TOF-MS, 93
- Prostate cancer, soy protein, genistein, beta catenin, frizzled, gene expression, Wnt-frizzled signaling, 245
- Prostate cancer, soy protein, genistein, beta catenin, metabolic pathway, gene expression, 111
- Prostate cancer, *TFPI2*, imprinting, bisulphite sequencing, chromatin immunoprecipitation, DNA methylation, 51
- Prostate carcinoma, selenium, metalloproteins, prostate, 81
- Prostate, selenium, metalloproteins, prostate carcinoma, 81
- Protein expression, antibody arrays, cytokines, ovarian cancer, gynecological malignancy, diagnosis, 129
- Protein phosphorylation, apoptotic cell isolation, RPA, Erk1/2, cisplatin, multi-antibody screening, annexin V, 279
- Protein-protein interactions, angiogenesis, CD147 antibodies, matrix metallo-proteinase(s), target validation experiments, review, 157
- Proteomic profile, mass spectrometry, difference gel electrophoresis, DIGE, EPHB6, breast cancer invasiveness, metastasis, tyrosine kinase-deficient, 253
- Proteomics, biological therapy, cancer therapy, serpin, a-1-antitrypsin, Ehrlich carcinoma, 147
- Proteomics, S100A8, S100A9, bladder cancer, serum, immunohistochemistry, clinical outcome, 181
- Quadruplex, triplex, i-motif, non-B DNA structure, epigenetics, evolution, scaling developmental complexity, 207
- Radiotherapy, laryngeal carcinoma, Ki-67, MSH2, p53, cyclin D1, tissue microarray, immunohistochemistry, profiling, 1
- Reduced folate carrier, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, cystathione- $\beta$ -synthase, review, 105
- Review, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, prognostic marker, target validation, therapeutic intervention, ALCAM/CD166, 231
- Review, angiogenesis, CD147 antibodies, matrix metallo-proteinase(s), protein-protein interactions, target validation experiments, 157
- Review, interleukin 6, interleukin 6 receptor, cachexia, cancer, 287
- Review, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, thymidylate synthase, reduced folate carrier, cystathione- $\beta$ -synthase, 105
- Review, thyroid cancer, genetic basis, gene therapy trials, mutations, antisense approach, combination approach, toxic gene therapy approach, 31
- Review, transforming growth factor- $\beta$ 1, diagnostics, interactome, metastasis, therapeutics, 217
- Reviews, 31, 105, 157, 217, 231, 287, 337
- RPA, apoptotic cell isolation, Erk1/2, cisplatin, multi-antibody screening, annexin V, protein phosphorylation, 279
- S100A8, S100A9, bladder cancer, serum, proteomics, immunohistochemistry, clinical outcome, 181
- S100A9, S100A8, bladder cancer, serum, proteomics, immunohistochemistry, clinical outcome, 181
- Scaling developmental complexity, triplex, i-motif, Quadruplex, non-B DNA structure, epigenetics, evolution, 207
- SELDI-TOF-MS, biomarkers, mass spectrometry, prostate cancer, progression, serum proteomic analysis, 93
- Selenium, metalloproteins, prostate, prostate carcinoma, 81
- Serological proteome approach, malignant melanoma, autoantibody, melanoma markers, two-dimensional gel electrophoresis, 2-DE, SERPA, 17
- SERPA, malignant melanoma, autoantibody, melanoma markers, two-dimensional gel electrophoresis, 2-DE, serological proteome approach, 17
- Serpin, biological therapy, cancer therapy, proteomics, a-1-antitrypsin, Ehrlich carcinoma, 147
- Serum proteomic analysis, biomarkers, mass spectrometry, prostate cancer, progression, SELDI-TOF-MS, 93
- Serum, S100A8, S100A9, bladder cancer, proteomics, immunohistochemistry, clinical outcome, 181
- Soy protein, prostate cancer, genistein, beta catenin, frizzled, gene expression, Wnt-frizzled signaling, 245
- Soy protein, prostate cancer, genistein, beta catenin, metabolic pathway, gene expression, 111
- SP600125, cell cycle regulation, apoptosis, endoreplication, microarray, c-jun N-terminal kinase, 87
- SPR spectroscopy, affinity enrichment, binding, biosensor, kinetics, label-free, mass, probe, photons, nucleic acid-protein interactions, 303
- Survival, mast cells, esophageal carcinoma, 25
- Survival, TACC2, breast cancer, transcript analysis, prognosis, 67
- Survivin, apoptosis, immunohistochemistry, tumour marker, p53, non-small cell lung cancer, 331
- TACC2, breast cancer, transcript analysis, survival, prognosis, 67
- Target validation experiments, angiogenesis, CD147 antibodies, matrix metallo-proteinase(s), protein-protein interactions, review, 157

- Target validation, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, prognostic marker, therapeutic intervention, ALCAM/CD166, review, 231
- TFPI2*, imprinting, prostate cancer, bisulphite sequencing, chromatin immunoprecipitation, DNA methylation, 51
- Therapeutic intervention, adhesion and aggregation, dissemination and metastasis, homo- and heterophilic interactions, malignant melanoma, prognostic marker, target validation, ALCAM/CD166, review, 231
- Therapeutics, transforming growth factor- $\beta$ 1, diagnostics, interactome, metastasis, review, 217
- Thymidylate synthase, meningiomas, folate metabolism, gene polymorphisms, methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, reduced folate carrier, cystathione- $\beta$ -synthase, review, 105
- Thyroid cancer, genetic basis, gene therapy trials, mutations, antisense approach, combination approach, toxic gene therapy approach, review, 31
- Tissue microarray, laryngeal carcinoma, Ki-67, MSH2, p53, cyclin D1, immunohistochemistry, profiling, radiotherapy, 1
- Toxic gene therapy approach, thyroid cancer, genetic basis, gene therapy trials, mutations, antisense approach, combination approach, review, 31
- Transcript analysis, TACC2, breast cancer, survival, prognosis, 67
- Transforming growth factor- $\beta$ 1, diagnostics, interactome, metastasis, therapeutics, review, 217
- Triplex, i-motif, Quadruplex, non-B DNA structure, epigenetics, evolution, scaling developmental complexity, 207
- Tumour marker, apoptosis, immunohistochemistry, p53, survivin, non-small cell lung cancer, 331
- Two-dimensional gel electrophoresis, 2-DE, malignant melanoma, autoantibody, melanoma markers, serological proteome approach, SERPA, 17
- Tyrosine kinase-deficient, mass spectrometry, difference gel electrophoresis, DIGE, proteomic profile, EPHB6, breast cancer invasiveness, metastasis, 253
- Wnt-frizzled signaling, prostate cancer, soy protein, genistein, beta catenin, frizzled, gene expression, 245



## Authors Index

(Figures refer to page numbers)

- Adra CN, 93  
 Ahmed FE, 303  
 Akiyama Y, 17  
 Al-Humadi H, 31  
 Al-Ruwaili JA, 93  
 Al-Saigh R, 31  
 Amandzholov BS, 147  
 Anifantaki F, 105  
 Anisimova NY, 147  
 Ansell CM, 311  
 Asplund A, 1  
 Aukim-Hastie CL, 93  
 Bartel Jens, 81  
 Bartel Jürgen, 81  
 Bartz T, 81  
 Bauer R, 191  
 Berger F, 87  
 Bergqvist M, 1, 25  
 Bergström S, 1, 25  
 Blomquist E, 1  
 Boechzelt H, 191  
 Bonnerup C, 303  
 Boutonnat J, 87  
 Burgkart R, 61  
 Burkholder B, 129  
 Carty MP, 279  
 Catchpoole DR, 323  
 Champelovier P, 87  
 Charkiewicz E, 81  
 Cheng S, 67  
 Collan Y, 143  
 Cruet-Hennequart S, 279  
 Datta MW, 111, 245  
 Davies ML, 75  
 Degueme A, 111, 245  
 Diehl P, 61  
 Distel RJ, 217  
 Donenko FV, 147  
 Douglas-Jones A, 67  
 Drakos SS, 105  
 Du-Quiton J, 311  
 Efferth T, 147, 191, 261, 337  
 Eggle D, 157, 231, 287  
 Ekman S, 1, 25  
 El Atifi-Borel M, 87  
 Engers R, 51  
 Farwell MA, 261  
 Fitzgerald R, 245  
 Fix LN, 261  
 Fodstad O, 75  
 Fox BP, 9  
 Fricker G, 191  
 Friedman A, 311  
 Goering W, 51  
 Gradinger R, 61  
 Graf M, 173  
 Grbavac I, 81  
 Hao X, 191  
 Hecht K, 173  
 Hellström K, 1  
 Hessner M, 111, 245  
 Hildebrandt B, 61  
 Holgersson G, 1  
 Hrushesky WJM, 311  
 Huang R, 129  
 Huang RF, 129  
 Huang R-P, 129  
 Huoponen K, 143  
 Iizuka A, 17  
 Ingenwerth M, 51  
 Ishii J-I, 181  
 Issartel J-P, 87  
 Jankowska R, 331  
 Jiang W, 129  
 Jiang WG, 67, 76  
 Jonnalagadda P, 1  
 Kageyama T, 181  
 Kahl S, 191  
 Kahler A, 245  
 Kandpal RP, 9, 253  
 Karamustafa S, 191  
 Kawashima Y, 181  
 Kiselevskii MV, 147  
 Kiyohara Y, 17  
 Klostermann S, 157, 231, 287  
 Klotz D, 191  
 Komiyama M, 17  
 Konkimalla VB, 191  
 Kosacka M, 331  
 Krüger A, 287  
 Kume A, 17  
 Kuo WP, 217  
 Kurusu A, 17  
 Kyriakopoulos A, 81  
 Laakso S, 143  
 Lacy JN, 217  
 Larkin SE, 93  
 Lehtonen J, 143  
 Lehtonen T, 143  
 Liapi C, 31, 105  
 Liljeholm M, 1  
 Linder A, 1  
 Liss MA, 111, 245  
 Liu H-Y, 191  
 Löden B, 1  
 Magdolen U, 61  
 Magnusson K, 1  
 Mahringer A, 191  
 Mansel RE, 67  
 Mao YQ, 129  
 Matsumoto K, 181  
 Matsumoto T, 181  
 Minami S, 181  
 Molin D, 25  
 Mota H, 303  
 Nagashio R, 181  
 Nakamura Y, 17  
 O'Meara E, 279  
 Oh E-Y, 311  
 Ohno-Machado L, 217  
 Ohshita C, 17  
 Okayasu I, 181  
 Parr C, 75  
 Pereira G, 337  
 Perera M, 217  
 Petrovici K, 173  
 Pfister K, 173  
 Pontén F, 1  
 Porebska I, 331  
 Pospiech H, 143  
 Quiton DF, 311  
 Reif S, 173  
 Reizenstein J, 1  
 Ribarska T, 51  
 Ricchiuti V, 217  
 Royer-Pokora B, 61  
 Saldamli B, 61  
 Samaranayake LP, 217  
 Sanders AJ, 75  
 Sato Y, 181  
 Schauwecker J, 61  
 Scheuer W, 157  
 Schlicht M, 111, 245  
 Schmetzer H, 173  
 Schmidt D, 81  
 Schmitt M, 61  
 Schulz WA, 51  
 Seigneurin D, 87  
 Shah M, 261  
 Sitdikova SM, 147  
 Smejkal GB, 217  
 Smith MG, 217  
 Smith SS, 207  
 Sobańska E, 331  
 Steinbrück L, 337  
 Stewart BW, 323  
 Stockinger H, 157  
 Strömberg S, 1  
 Suzuki A, 17  
 Swart GWM, 231  
 Syväoja J, 143  
 Szymas J, 143  
 Tai S, 17  
 Takikawa M, 17  
 Taylor MG, 93  
 Thomassi T, 245  
 Tinge B, 25  
 Townsend PA, 93  
 Trachtenberg AJ, 217  
 Tsang CS, 217  
 Tübel J, 61  
 Uhlén M, 1  
 Voyushin KE, 147  
 Wakelin LPG, 323  
 Wang J, 191  
 Wang Y, 191  
 Weidle UH, 157, 231, 287  
 Weidner DA, 303  
 Wiley JE, 303  
 Wood PA, 311  
 Yamamoto A, 17  
 Yamazaki N, 17  
 Yang D, 129  
 Yang J, 129  
 Yang W, 129  
 Yang X, 311  
 Yang X, 67  
 Yoshikawa S, 17  
 Yoshio K, 181  
 Zarros A, 31, 105  
 Zeidan BA, 93  
 Zhang B, 261  
 Zhang Y, 129  
 Zhou Q, 143  
 Ziganshin RH, 147  
 Zihlif M, 323





## Errata

Volume 5 (2008), Number 3-4, page 151: The authors of this article sent the following note:

Based on our recent study and confirm with previous published paper (Jianping Jin, Timothy Cardozo, Ruth C. Lovering, Stephen J. Elledge, Michele Pagano and J. Wade Harper, *GENES & DEVELOPMENT* 18: 2573-2580, 2004), we would like to make a knowledgeable correction for our paper published in *Cancer Genomics Proteomics* [Xiao GG, Zhou BS, Somlo G, Portnow J, Juhasz A, Un F, Chew H, Gandara D and Yen Y: Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy. *Cancer Genomics Proteomics* 5(3-4): 151-160, 2008]. In our original report, we identified F-box/LLR-repeated protein 17 (FBXL17), but assigned this protein as FBXL17/Skp2. At this time, we think that our original report about FBXL17/Skp2 was inappropriate and confusing although FBXL17 and Skp2 are sharing similar sequence (belonging to the same superfamily member, F-box protein family). Therefore, we want to make this correction. The correct protein identified should be FBXL17 instead of FBXL17/Skp2.

Volume 7, Number 3, page 143: Line 7 of introduction should read:  
subunit is located on chromosome 14 (2). An antibody that

Volume 7, Number 3, page 143: Right column, line 5 should read:  
and produces a unique spectrum of spontaneous neoplasms,

Volume 7, Number 3, page 144: Left column, line 19 should read:  
first fresh frozen at  $-130^{\circ}\text{C}$  and cryostat cut for diagnosis. The

Volume 7, Number 3, page 145: Left column, line 4 should read:  
large deletions. The SSCP method is relatively simple and of

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org), [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org)

**Publication Data:** CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org) (Editorial Office), [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org) (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

**Annual Subscription (print and online) Rates 2011:** Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. Prices include rapid delivery and insurance. Previous volumes (2004-2010) are available at 50% discount.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece, and should be sent to the Editorial Office.

**Advertising:** Correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.